1. Targeted Protein Degradation: from Chemical Biology to Drug Discovery
Philipp M. Cromm, Craig M. Crews 
Cell Chemical Biology 
Volume 24, Issue 9, Pages (September 2017)
DOI: /j.chembiol
Copyright © 2017 Elsevier Ltd Terms and Conditions

2. Figure 1 Pharmacology Models
Many diseases are caused by abnormal protein function. Occupancy-driven pharmacology blocks malfunctioning proteins via inhibition, i.e., applying high concentrations of inhibitor. In event-driven pharmacology, protein function is controlled by decreasing the cellular protein level. The disease-implicated protein is displayed in dark yellow, the applied inhibitor in red.
Cell Chemical Biology  , DOI: ( /j.chembiol )
Copyright © 2017 Elsevier Ltd Terms and Conditions

3. Figure 2 The Ubiquitination Machinery
(A) ATP-dependent ubiquitin activation by ubiquitin-activating enzyme (E1) and transfer to an ubiquitin-conjugating enzyme (E2) results in an E2-Ub intermediate.
(B) For RING E3s, ubiquitin is directly linked to the protein of interest (POI) after simultaneous binding to E2-Ub and POI.
(C) Simplified schematic blueprint of a Cullin RING E3. Cullin RING E3s are multi-subunit RING ligases comprising an F box protein for substrate recognition, a RING domain for E2-Ub binding, and additional regulatory proteins (omitted for simplicity; more detailed information about Cullin RING ligases can be found elsewhere; Hua and Vierstra, 2011).
(D) Homologous to the E6AP C terminus (HECT)- and RING-between-RING (RBR)-type E3s catalyze the ubiquitin transfer in a two-step process. Before ubiquitin is tethered to the POI it is trans-thiolated to the active site of the E3.
Cell Chemical Biology  , DOI: ( /j.chembiol )
Copyright © 2017 Elsevier Ltd Terms and Conditions

4. Figure 3 Small-Molecule Protein-Degradation Techniques
(A) HyTs degrade their protein target via a not fully elucidated mechanism following one of two possible pathways. (a) HyT binding destabilizes the POI, which recruits a chaperone that induces POI proteasomal degradation. (b) The chaperone recognizes the HyT directly and marks the tagged POI for destruction.
(B) PROTAC mode of action. The bifunctional PROTAC binds simultaneously to the POI and an E3, bringing both proteins in spatial proximity and inducing ubiquitination. The ubiquitinated POI is subsequently degraded by the proteasome releasing the PROTAC. Both approaches, HyT and PROTACs, can traverse multiple circles allowing for substoichiometric usage.
Cell Chemical Biology  , DOI: ( /j.chembiol )
Copyright © 2017 Elsevier Ltd Terms and Conditions

5. Figure 4 Structural Elucidation of E3 Ligand Binding
(A) Crystal structure of nutlin 3a bound to its target protein MDM2 (PDB: 4HG7).
(B) The VHL ligand 1 provides the essential hydroxyproline to engage the F box protein VHL (PDB: 4W9H).
(C) Pomalidomide bound to its molecular target the F box protein CRBN (PDB: 4TZU).
Sites of linker attachment are highlighted by a black arrow.
Cell Chemical Biology  , DOI: ( /j.chembiol )
Copyright © 2017 Elsevier Ltd Terms and Conditions

6. Figure 5 Small-Molecule PROTACs Targeting BET Proteins
Cell Chemical Biology  , DOI: ( /j.chembiol )
Copyright © 2017 Elsevier Ltd Terms and Conditions

7. Figure 6 Structural Insight into PROTAC Mode of Action
(A) Binding interface between BRD4 (dark gray) and VHL (gray) with MZ1 (light orange) embedded in a bowl-shaped cavity formed by both proteins. The warhead JQ1, as well as E3 recruiting VHL ligand 1, form contacts with both proteins BRD4 and VHL.
(B) Upon formation of the ternary complex BRD4 and VHL engage in extensive PPIs resulting in high cooperativity.
(C) Rationally designed BRD4 selective PROTAC AT1 (PDB: 5T35).
Cell Chemical Biology  , DOI: ( /j.chembiol )
Copyright © 2017 Elsevier Ltd Terms and Conditions